Breast Cancer

So many friends I have met along the way wanted so badly to live and they weren't able to. They didn't lose and I didn't win. We all walked through something really hard and got different outcomes.

Nurse practitioner Bridget Hopkins discusses her metastatic breast cancer diagnosis, the role of clinical empathy and finding hope in stage 4 care.

Three lifelong friends, all breast cancer survivors, discuss the strength they found in supporting each other.

Dr. Wendy Woodward discussed the transformative rise of hypofractionated radiation.

Dr. Hope Rugo and advocate Jonise Louis discuss new ADCs, biomarker testing, and patient-centered dosing for metastatic triple-negative breast cancer.

The FOURLIGHT-1 study found that atirmociclib plus Faslodex significantly improved progression-free survival in patients with HR+/HER2- metastatic breast cancer.

A phase 3 trial update for GLSI-100 shows a recurrence rate of less than 1% per year in patients with HER2-positive breast cancer after immunization.

Dr. Don S. Dizon presented information on pregnancy with a breast cancer diagnosis and what patients should know.

A daughter’s cancer journey shows that survivorship is filled with constant waiting—from tests and treatment to life milestones — where each result can bring relief or fear.

Learn about male breast cancer, including common symptoms, diagnostic tests and how hormone therapy or surgery is used to treat this rare disease.

Dr. Anastasia Tousimis explores the feasibility, risks and surgical techniques for performing NSM in radiated patients to ensure oncologic safety.

That’s what I need to remember: Not made-up scenarios, but that if I’m open, truly open, to whatever life has in store, it will be OK.

A study of 922 patients shows the Aida test predicts 10-year recurrence risk and helps guide radiation decisions for invasive breast cancer.

A structured exercise program may reduce cognitive decline, often referred to as “chemo brain,” in patients receiving chemotherapy for the first time.

Preliminary INVINCIBLE-4 study data shows INT230-6 plus standard care may increase pathological complete response rates and improve patient safety.

The phase 3 persevERA study of giredestrant plus Ibrance missed its PFS goal, though positive data from other trials supports the drug.

FDA grants priority review to Enhertu for patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant treatment.

Clinical trial data show a carboplatin-free regimen offers similar results with fewer side effects for patients with stage 2 to 3 HER2+ disease.

Zovegalisib plus Faslodex elicited responses in patients with HR-positive, HER2-negative, PIK3CA-mutant advanced breast cancer.

Here are five key takeaways regarding the use of GLP-1 receptor agonists in patients who are undergoing breast cancer treatment.

At the Miami Breast Cancer Conference, Dr. Heather A. Parsons shared growing evidence for the prognostic value of circulating tumor DNA.

New data show that Enhertu had similar safety in the real world as in clinical trials in patients with HER2-low metastatic breast cancer.

A community study finds Enhertu effective for HER2-low mBC, with over half of patients seeing tumor shrinkage and high one-year survival rates.

New data show more women over 70 are safely skipping sentinel lymph node biopsies for HR+ breast cancer, reducing unnecessary surgery and risks.

After abnormal mammogram, family history and testing revealed a BRCA1 mutation, leading one woman to choose preventive surgeries and share her experience.